Application analysis of hypoglycemic drugs in our hospital during 2008-2012

LONG Xiao-yun; ZHOU Yang; WEI Guo-yi

doi:10.3969/j.issn.1672-8157.2013.04.013

Abstract：Objective:To understand the application of hypoglycemic drugs and the new glucagon-like peptide 1 (GLP-1) in our hospital. Methods:Analysis was based on data of the amount of delivered drugs during 2008 to 2012 documented in hospital information system. Consumption sum ranking and frequency analysis methods were performed. DDDs and defined daily cost (DDC) were calculated and ranked according to defined daily dose (DDD). Results:The consumption sum of hypolycemic agents in our hospital increased rapidly and continuously.Consumption sum of insulins including its analogues andα-glucosidase inhibitors was similar with increasing shares to 30%, respectively, was in top two positions for five years. DDDs of acarbose increased by twice and was in the first place continuously, while DDDs of metformin (glucophage) rose to the second in 2012 from the third place in 2009 with an increasing of 1.86 times. In addition, DDC of metformin was always in the last three places and decreased from 6.48 yuan in 2008 to 5.84 yuan in 2012. GLP-1 receptor agonist exenatide was introduced into our hospital in 2012. Conclusion:Demand of hypolycemic agents increased year by year in our hospital. There were various categories of hypolycemic agents. The new type drug was available.